𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-γ

✍ Scribed by Takanobu Irie; Masahiko Tsujii; Shingo Tsuji; Toshiyuki Yoshio; Shuji Ishii; Shinichiro Shinzaki; Satoshi Egawa; Yoshimi Kakiuchi; Tsutomu Nishida; Masakazu Yasumaru; Hideki Iijima; Hiroaki Murata; Tetsuo Takehara; Sunao Kawano; Norio Hayashi


Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
610 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Cyclooxygenase‐2 (COX‐2) inhibitors are effective chemopreventive agents against colorectal cancers. For treatment of advanced cancers, combination of COX‐2 inhibitors and chemotherapy has been attempted, but the results are still controversial. In the present study, the effects of the COX‐2 inhibitor celecoxib on the anticancer potential of chemotherapy, and its mechanisms of action were investigated in point of the angiogenesis, using an advanced cancer model in mice. BALB/c mice were inoculated with colon 26 cells. After the allograft grew up to 5 mm in diameter, the animals received celecoxib, 5FU, or a combination of 5FU and celecoxib (5FU/celecoxib). After 21‐days of the treatment, 5FU/celecoxib significantly inhibited the tumor growth and the tumor vessel density compared with the other groups. Celecoxib, 5FU or 5FU/celecoxib significantly suppressed the VEGF content in tumor tissues. 5FU/celecoxib also enhanced IFN‐γ levels in tumor tissue, which could be involved in the potent antitumor effects of 5FU/celecoxib. This hypothesis was proven, because in IFN‐γ knockout (IFN‐γ^−/−^) mice, the inhibitory effects of 5FU/celecoxib on angiogenesis and tumor growth were significantly impaired compared with that in wild type mice. These results suggest that celecoxib enhances the antitumor effect of 5FU against an advanced colon cancer model by suppressing angiogenesis. In addition to VEGF, IFN‐γ has pivotal roles in tumor suppression induced by celecoxib. © 2007 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Synergistic antitumor effects of FGFR2 i
✍ Masakazu Yashiro; Osamu Shinto; Kazunori Nakamura; Masashige Tendo; Tasuku Matsu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 902 KB

## Abstract Scirrhous gastric carcinoma (SGC) carries the highest mortality because of a frequent metastasis to lymph node (LN). S1, a 5‐fluorouracil (5‐FU) analog, is clinically available for gastric cancer at an advanced stage. Fibroblast growth factor receptor 2 (FGFR2) is required for the proli

The effects of γ-interferon combined wit
✍ Ingrid W. H. M. Maas; Epie Boven; Herbert M. Pinedo; Hennie M. M. Schlüper; Hidd 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 840 KB

Gamma-Interferon (IFN-y) and the antimetabolites 5fluorouracil(5-FU) and 5-fluoro-2'-deoxyuridine (FUdR) were investigated as individual agents and in combination for their in vitro antiproliferative capacity and for their effect on the expression of HLA class-I antigen, carcinoembryonic antigen (CE